NCT04111497View on ClinicalTrials.gov

Glasdegib for Chronic Graft-Versus-Host Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions

Chronic Graft Versus Host DiseaseFasciitis

Interventions

DRUG

Glasdegib

Given PO

Trial Locations (3)

27710

Duke University Medical Center, Durham

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT04111497 - Glasdegib for Chronic Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter